25.60010.18% ( -2.900 )
Trading: Nov 16, 10:23:20 (EDT)Valuation
Current Valuation
-24.25xP/E
$28.50Stock price
$-1.18Earnings per share
-24.25xP/E
Stock price$28.50Earnings per share$-1.18
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.98x | 162.72% | $208.48B |
MRNAUSModerna | -31.97x | 1.41% | $89.18B |
CSLLYUSCSL Limited | -25.56x | -- | $65.92B |
NTRAUSNatera | -280.91x | 2.42% | $46.27B |
RVMDUSRevolution Medicines | -19.74x | 40.80% | $36.93B |
ROIVUSRoivant Sciences | -83.18x | 102.68% | $28.64B |
INSMUSInsmed | -43.89x | 74.47% | $26.58B |
BNTXUSBioNTech SE | -12.54x | 29.49% | $21.22B |
BBIOUSBridgebio Pharma | -25.76x | 31.00% | $15.25B |
SMMTUSSummit Therapeutics | -13.56x | 24.22% | $11.29B |
BMRNUSBioMarin Pharma | -579.92x | 56.09% | $11.09B |
KYMRUSKymera Therapeutics | -30.36x | 8.74% | $10.61B |
PCVXUSVaxcyte | -8.73x | 42.58% | $10.03B |
MDGLUSMadrigal Pharma | -63.86x | 86.93% | $9.93B |
SYREUSSpyre Therapeutics | -44.09x | 59.92% | $9.88B |
PRAXUSPraxis Precision Medicines | -25.52x | 1.10% | $9.17B |
RYTMUSRhythm Pharma | -40.21x | 51.65% | $7.97B |
ALKSUSAlkermes | -22,515.92x | 134.09% | $7.90B |
CYTKUSCytokinetics | -10.05x | 8.60% | $7.82B |
TWSTUSTwist Bioscience | -56.43x | 35.51% | $7.35B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
